News

The neurologist at Cleveland Clinic discusses the clinical considerations included in the decision to stop treatment of MS in patients with progressive disease.

In Part 1 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, shared her experiences with a number of new migraine drugs and devices and the impact that more options will have on clinical practice.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

The breakthrough study is a concrete example of the opportunities that precision medicine present in the pursuit to prevent the onset of or worsening of diseases like Alzheimer dementia.

Bogged down by a decades-long chase for a common pathology, investigators exploring alternative and complimentary theories are pushing to extend their time in the spotlight.

Study results suggest that adherence to individually tailored interventions, including behavioral, dietary, pharmacologic, educational, and other recommendations can have a positive impact on cognition and reduce risk in patients across the clinical spectrum who have a family history of Alzheimer disease.

The staff neurologist at Cleveland Clinic addressed several questions regarding choosing an optimal therapy for patients with MS.

The drug, which is currently approved for single-dose intravenous administration in patients with SMA type 1, is currently being investigated as intrathecal therapy in SMA type 2.

The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.

A phase 3 study of celecoxib oral solution showed statistically significant improvements in the acute treatment of episodic migraine.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Robert Fox, MD, reviews the current treatment landscape for progressive multiple sclerosis, and why a focus on inflammation may not be sufficient to slow disease progression.

Although the indication of pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage psychosis symptoms.

The benefits of lowering systolic blood pressure for stroke prevention and reducing poststroke disability are numerous, but the ideal target remains elusive.

Robert Fox, MD, discussed the pursuit to identify new imaging biomarkers in an effort to better understand the disease course in progressive multiple sclerosis.

Study results show that deflazacort tops prednisone across multiple checkpoints in patients with Duchenne muscular dystrophy.

Reisa Sperling, MD sat down with NeurologyLive to discuss why she thinks investigational drugs for Alzheimer disease are failing, and what she feels are the most promising treatment avenues.

Krithika Subramanian, PhD discusses the orexin receptor pathway, signals within orexin receptors, and much more surrounding the clinical application of orexin receptor antagonists.

Neurology News Network for the week ending October 26, 2019.

NeurologyLive's editor in chief Stephen D. Silberstein, MD, discusses the importance of considering treatment contraindications in the context of individual patients.

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

The drug is now approved to treat pediatric patients with both upper and lower limb spasticity, excluding spasticity caused by cerebral palsy.

VTS-72 is a proprietary combination of fumarate and VTS-Aspirin believed to improve the pharmacokinetics of fumaric acid while improving flush, which is estimated to occur in up to 40% of patients on a fumarate agent.

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic laid out these challenges that he and his colleagues face in differentiating patients with Lewy body dementia from other dementia pathologies.

The agency sent a joint letter with the FTC to Rooted Apothecary LLC for claiming its CBD products can medically treat a number of conditions including Alzheimer disease and Parkinson disease. Since 2017, the FDA has issued more than 10 such letters.

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.